Article Text

Download PDFPDF
Organising pneumonia due to inadequately cleared COVID-19 infection while on rituximab
  1. Caroline G. Olson,
  2. Christian Karime and
  3. Nancy Dawson
  1. Division of Internal Medicine, Mayo Clinic in Florida, Jacksonvile, Florida, USA
  1. Correspondence to Dr Caroline G. Olson; carolinegolson{at}gmail.com

Abstract

A male patient in his 70s with a history of tobacco use, organising pneumonia and rheumatoid arthritis that had been treated for several years with rituximab currently being treated with tocilizumab, presented with progressively worsening shortness of breath, increasing oxygen requirements and weakness. He had a history of COVID-19 infection 6 months prior to presentation. Initial COVID-19 PCR testing at presentation was negative. Bronchoalveolar lavage was positive for COVID-19 but negative for spike antibodies. It was thought that he did not clear his prior COVID-19 infection due to his immunocompromised state while taking rituximab. On recommendation of infectious disease, he was treated with a prolonged course of nirmatrelvir/ritonavir, remdesivir and corticosteroids with significant symptom improvement.

  • COVID-19
  • Pneumonia (infectious disease)
  • Pneumonia (respiratory medicine)
  • Drugs: musculoskeletal and joint diseases

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content: CO, CK and ND. The following authors gave final approval of the manuscript: CO, CK and ND. Guarantor is ND.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.